



Attorney Docket No.: 6258.200-US

PATENT

RECEIVED
TECH CENTER 1600/2900
MAR 21 2003

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Madsen et al.

Serial No.: 09/996,023

Group Art Unit: 1626

Filed: November 16, 2001

Examiner: Stockton, Laura Lynne

For: Glucagon Antagonists/Inverse Agonists

Confirmation No.: 2060

12

TERMINAL DISCLAIMER UNDER 37 CFR 1.321(a)

Assistant Commissioner for Patents
Washington, DC 20231

Sir:

I am an attorney of record for the instant application.

Novo Nordisk A/S and Agouron Pharmaceuticals Inc. are the assignees of the entire interest in the above-identified application as evidenced by the assignment from the named inventors to Novo Nordisk A/S and Agouron Pharmaceuticals Inc. in the present application 09/996,023 that was recorded on February 28, 2002 at Reel 012657, Frame 0626.

The terminal part of the statutory term of any patent granted on the above-identified application, which would extend beyond the expiration date of the full statutory term of U.S. Patent No. 6,503,949, issued January 7, 2003, is hereby disclaimed, except as provided below, and it is agreed that any patent so granted on the above-identified application shall be enforceable only for and during such period that the legal title to said patent shall be the same as the legal title to U.S. Patent No. 6,503,949, issued January 7, 2003, this agreement to run with any patent granted on the above-identified application and to be binding upon the grantee, its successors and assigns.

In making the above disclaimer, disclaimant does not disclaim the terminal part of any patent granted on the above-identified application that would extend beyond the expiration date of the full statutory term of U.S. Patent No. 6,503,949, issued January 7, 2003,

03/20/2003 0000133 141447 09996023
01 FC:1814 110.00 CH

in the event that the latter later expires for failure to pay a maintenance fee, is held unenforceable, is found invalid by a court of competent jurisdiction, is statutorily disclaimed in whole or terminally disclaimed under 37 CFR 1.321, has all claims canceled by a reexamination certificate, is reissued in any matter or is terminated prior to expiration of its full statutory term as presently shortened by any terminal disclaimer, except for the separation of legal title stated above.

Please charge the fee required under 37 C.F.R. 1.20(d) for the filing of this Terminal Disclaimer, estimated to be \$110.00, to Deposit Account No.14-1447. A duplicate of this sheet is enclosed.

Respectfully submitted,

Date: March 11, 2003

Richard W. Bork
Richard W. Bork, Reg. No. 36,459
Novo Nordisk Pharmaceuticals, Inc.
100 College Road West
Princeton NJ 08540
(609) 987-5800

